Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Bryce P. Portier

Bryce P. Portier, MD, Ph.D.

Medical Director, Solid Tumor Molecular Diagnostics
Department of Pathology and Genomic Medicine
Houston Methodist Hospital Physician Organization

6565 Fannin Street, Suite M227
Houston, Texas 77030
Phone: 713-441-1771
Email: bpportier@houstonmethodist.org

Biography

Dr. Portier received his M.D. and Ph.D. degrees at The University of Texas Medical Branch in Galveston in 2008. He then completed pathology residency at the Cleveland Clinic and a fellowship in molecular genetic pathology at The University of Texas MD Anderson Cancer Center in Houston. Dr. Portier has received numerous awards and honors throughout his education and training, including a Young Investigator Award from the Association of Molecular Pathology, a Scholar-in-Training Award from the American Association for Cancer Research, and a Ruth L. Kirschstein Institutional National Service Award from the National Institutes of Health. Dr. Portier joined Houston Methodist Hospital Physician Organization in 2013.

Dr. Portier is a general surgical pathologist with subspecialty interest in molecular genetic pathology. His research centers on the identification and validation of novel molecular biomarkers in breast and gastric carcinomas. He currently holds a provisional patent with a pharmaceutical partner for a breast oncology panel that assesses metastasis-free survival using a novel IHC signature.

Representative Recent Publications

  • Minca EC, Portier BP, Wang Z, Lanigan C, Farver CF, Feng Y, Ma PC, Arrossi VA, Pennell NA, Tubbs RR. ALK Status Testing in Non-Small Cell Lung Carcinoma: Correlation Between Ultrasensitive IHC and FISH. J Mol Diagn. 2013 Mar 13. [Epub ahead of print]
  • Wang Z, Portier BP, Gruver AM, Bui S, Wang H, Su N, Vo HT, Ma XJ, Luo Y, Budd GT, Tubbs RR. Automated Quantitative RNA in Situ Hybridization for Resolution of Equivocal and Heterogeneous ERBB2 (HER2) Status in Invasive Breast Carcinoma. J Mol Diagn. 2013 Mar;15(2):210-9.
  • Portier BP, Wang Z, Downs-Kelly E, Rowe JJ, Patil D, Lanigan C, Budd GT, Hicks DG, Rimm DL, Tubbs RR. Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistry. Mod Pathol. 2013 Jan;26(1):1-9.
  • Patil DT, Bronner MP, Portier BP, Fraser CR, Plesec TP, Liu X. A five-marker panel in a multiplex PCR accurately detects microsatellite instability-high colorectal tumors without control DNA. Diagn Mol Pathol. 2012 Sep;21(3):127-33.
  • Wang Z, Portier BP, Hu B, Chiesa-Vottero A, Myles J, Procop GW, Tubbs RR. Diagnosis of BK viral nephropathy in the renal allograft biopsy: role of fluorescence in situ hybridization. J Mol Diagn. 2012 Sep;14(5):494-500.
  • Portier BP, Gruver AM, Huba MA, Minca EC, Cheah AL, Wang Z, Tubbs RR. From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma. N Biotechnol. 2012 Sep 15;29(6):665-81.
  • Gruver AM, Portier BP, Tubbs RR. Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med. 2011 May;135(5):544-57.
  • Portier BP, Hansel DE, Zhou M, Maclennan GT. Mixed epithelial and stromal tumor of the kidney. Urol. 2009 Apr;181(4):1879-80.
  • Portier BP, Taglialatela G. Bcl-2 localized at the nuclear compartment induces apoptosis after transient overexpression. J Biol Chem. 2006 Dec 29;281(52):40493-502.
  • Portier BP, Ferrari DC, Taglialatela G. Rapid assay for quantitative measurement of apoptosis in cultured cells and brain tissue. J Neurosci Methods. 2006 Jul 15;155(1):134-42.